Kornimate/medical-research-clean huggingface dataset:
strength and function following total hip arthroplasty

Conditions: Total Hip Arthroplasty

Summary: to determine if patients who receive an 8 week, comprehensive, multi-component rehabilitation program (cmc) have better strength and functional performance compared to a control group (con). the investigators hypothesize that functional performance and strength in the muscles surrounding the hip and the knee will be greater in the multi-component rehabilitation group compared to the control group.

the participants will be enrolled and following surgery, randomized into one of two treatment groups (cmc or con). prior to randomization, both groups will participate in two weeks of home rehabilitation consisting mobility training and activities of daily living. after randomization, the cmc group will receive physical therapy 2x/ week for 8 weeks from a licensed physical therapist and member of the investigative team starting 2 weeks after total hip arthroplasty (tha). the con group will continue activities provided by their home rehabilitation therapist for 8 weeks. the con group will then participate in the cmc intervention beginning 10 weeks after tha. these patients will complete pre-operative and post-operative testing as described above. the cmc group will receive a multi-component program focused on rehabilitation of the abdominal and core musculature, neuromuscular re-education through therapeutic exercise as well as hip and knee muscle strengthening beginning 2 weeks after tha. the con group will participate in physical therapist recommended activities based on their home rehabilitation and then will complete the same multi-component rehabilitation intervention beginning 10 weeks after tha.

Eligibility criteria:
inclusion criteria: * receiving a total hip replacement secondary to md diagnosed end-state osteoarthritis only * cognitive status that allows patients to consistently comprehend and repeat back directions regarding the details of the study. exclusion criteria: * hba1c levels greater than 7% based on medical records * neurological, vascular or cardiac problems that limit function * moderate or severe osteoarthritis or other orthopaedic conditions in the non-operated lower extremity * lower back pain which interferes with activities of daily living * diagnosed disease which affects muscle function (parkinson's, fibromyalgia, multiple sclerosis) * history of vestibular dysfunction * body mass index greater than 40 * alcoholism or drug abuse

Keywords: total hip arthroplasty muscle strength hip osteoarthritis
a novel device for the treatment of postural hypotension - a signal of effectiveness study.

Conditions: Orthostatic Hypotension

Summary: the goal of this clinical trial is to test a novel medical device (iso-101) in patients diagnosied with orthostatic hypotension. the main question\[s\] it aims to answer are: * to determine whether the iso-101 device demonstrates a signal of efficacy in people with oh and whether it is worthy of further clinical evaluation. * assess the safety and performance of the iso-101 device in patients with orthostatic hypotension. participants will use the device under controlled conditions and have the following parameters measured before and after standing up: * blood pressure * markers of peripheal vascular resistence * sympathetic nervous system activity measure before and after standing up

this is a proof of principle study aimed at evaluating if there is a signal of efficacy from use of the iso-101 device in people with orthostatic hypotension. the study is a single centre, unblinded, pre-post study. all participants will act as their own control, and all will receive the intervention.the primary objective is to determine whether the iso-101 device demonstrates a signal of efficacy in people with oh and whether it is worthy of further clinical evaluation.

Eligibility criteria:
inclusion criteria: * willing and able to give informed consent for participation in the study * adults aged over 18 years with a clinical diagnosis of orthostatic hypotension * a drop in systolic bp of ≥20 mmhg (with or without a drop in diastolic bp ≥10 mmhg) within 3 minutes of standing up from a supine position * able to stand up from a supine position (with assistance if required) exclusion criteria: * cognitively unable to follow research procedures * physically unable to use the iso-101 device (e.g., unilateral arm weakness due to stroke) * acute or reversible cause of oh (e.g., haemorrhage or sepsis) * current pregnancy * participants on insulin (participants will be asked to refrain from breakfast on the morning of their assessment) * resting supine systolic bp ≥180 or diastolic ≥110 mmhg
influence of custom orthosis post carpometacarpal (cmc) arthroplasty

Conditions: Thumb Osteoarthritis

Summary: this study aims to compare post-surgical outcomes of individuals who receive either a custom orthosis or prefabricated splint after carpometacarpal arthroplasty.

this research study will randomly assign subjects post cmc arthroplasty to intervention a (prefabricated splint) or intervention b (custom orthosis). the orthosis and splint being used in this study are both considered standard practice. subjects will be provided the splint or orthosis at the first post-operative appointment. subjects who are assigned to intervention a will be provided a pre-fabricated splint by a member of the surgical team. subjects who are assigned to invention b will be evaluated by an occupational therapist and a custom orthosis will be fabricated. outcome measures include: quickdash, pain visual analogue scale, active range of motion measurements, the applied dexterity portion of the arthritis hand function test except for the putty cutting task, edema, sandy grading score and the orthotics and prosthetics user's survey (opus) satisfaction with device and services. data will be collected at the first, second, and third post-operative appointment.

Eligibility criteria:
inclusion criteria: * status post cmc arthroplasty * 18 or older * able to read and understand english * capable of independently consenting to health care procedures. exclusion criteria: * if the surgeon identifies risk factors that would preclude random assignment to the control or experimental group * if subject requests a prefabricated or custom orthosis.

Keywords: carpometacarpal thumb arthroplasty splints function
comparison of infusion methods for hysteroscopic procedures

Conditions: Complication of Surgical Procedure

Summary: this study is to perform a randomized controlled trial of comparing the manual syringe infusion method with the conventional pump infusion method to clarify if the manual syringe infusion method really needs less amount of distension medium.

hysteroscopy is frequently used for diagnosing abnormal uterine bleeding, endometrial polyp or submucous myoma. however, hysteroscopic procedure can cause morbidity and even mortality related to infusion distension medium. we had used a manual syringe infusion method to infuse fluid for distending the uterine cavity in our institute without significant morbidity, and it seems that this method need less amount of distension medium, and possible result in less possibility of hyponatremia. therefore, the aim of this study is to perform a randomized controlled trial of comparing the manual syringe infusion method with the conventional infusion pump method to clarify if the manual syringe infusion method really needs less amount of distension medium during hysteroscopy.

Eligibility criteria:
inclusion criteria: * of greater than twenty-year-old female patients suffering from abnormal uterine bleeding, suspected endometrial lesions, endometrial polyp, or submucous myoma. exclusion criteria: * female patients of less than twenty years-old.

Keywords: hysteroscopy, water intoxication, hyponatremia
probiotics and overreaching recovery

Conditions: Fatigue; Muscle, Heart; Immunosuppression

Summary: overloading is a key training principle used by athletes and coaches to improve physical performance. intensified training periods are therefore commonly incorporated into the course of a regular training season. from a clinical point of view, very intense periods of training are associated with a temporary immunological deficiency which can lead to teh "overreaching syndroms". during periods of overreaching, nutritional strategies are mainly aimed at ensuring sufficient amounts of energy to support the increase in effort. however less is known about nutritional supplements to attenuated the inflammatory/immunological response to training stress. probiotic bacteria are defined as live food ingredients beneficial to the host's health. numerous health benefits have been attributed to probiotics, including effects on gastrointestinal tract function and disease, immune function, hyperlipidemia, hypertension, and allergic conditions. studies in the literature on the ergogenic effect of probiotics in athletes are still scarce today. this study aims to explore the potential role of probiotics on performance, recovery from fatigue and immune function during intensive period of training.


Eligibility criteria:
inclusion criteria: * age 25-55 years * body mass index:\> 18 and \<30 kg / m2 * stable body weight for at least 3 months * regular practice of physical activity for at least 2 years exclusion criteria: * chronic diseases (cardiovascular, hepatic, respiratory, cancer) * acute inflammatory states, infections or other pathologies * regular use of probiotics * use or treatment with steroids (within the previous 3 months)
open label study: treatment of als fatigue with polymva

Conditions: Amyotrophic Lateral Sclerosis

Summary: amyotrophic lateral sclerosis (als) is a disease that causes the death of upper and lower motor neurons. als symptoms are characterized by stiffness, muscle twitching, and worsening weakness due to muscle breakdown. onset of symptoms are typically arm or leg weakness or difficulty speaking or swallowing and gradual development of overall body weakness. the cause is unknown and there is no cure for als. poly mva was found to substantially lower fatigue and improve quality of life in a pilot study of patients with varied medical disorders. the reduction in fatigue was also observed in a small series of patients enrolled in an open label study for patients with gliomas. in this study, we want to find out more about a dietary supplement, called poly mva (also called the study drug in this form), for people with als. we want to find out if poly mva reduces the symptoms of fatigue and depression when taken daily. the supplement contains vitamins, minerals and amino acids (proteins) and has been used by patients with other medical conditions to help with their fatigue and quality of life.

amyotrophic lateral sclerosis (als) is a disease that causes the death of upper and lower motor neurons. als symptoms are characterized by stiffness, muscle twitching, and worsening weakness due to muscle breakdown. onset of symptoms are typically arm or leg weakness or difficulty speaking or swallowing and gradual development of overall body weakness. the cause is unknown and there is no cure for als. poly mva is a dietary supplement which contains a uniquely formulated combination of minerals, vitamins, and amino acids designed to promote cellular energy production. the active molecule in this supplement is palladium lipoic acid (pdla) complex. this compound is synthesized using a process whereby palladium (a rare metal, which is found in the food chain- we consume approximately 2 ng/day is chemically bound to alpha lipoic acid, a powerful anti-oxidant involved in cellular energy. poly mva was found to substantially lower fatigue and improve quality of life in a pilot study of patients with varied medical disorders. the reduction in fatigue was also observed in a small series of patients enrolled in an open label study for patients with gliomas. specific aim 1: to test the efficacy of polymva as a treatment for als fatigue. specific aim 2: to determine the specificity of the fatigue reducing effect of poly-mva by controlling for mood, disease severity, and cognitive status this is an open-label, prospective study which evaluates the response of 4 teaspoons of poly mva taken daily, over a 24-week interval.

Eligibility criteria:
inclusion criteria: * definite als * severe fatigue (defined by fss \> 4.0) * expanded disability status scale (edss) (measure of neurological impairment) 0 - 7.5 able to comply with study procedures * stable medication for the past month prior to enrollment. exclusion criteria: * na
evaluation of trimethylamine n-oxide (tmao) levels in periodontal disease

Conditions: Periodontitis; Inflammation; Trimethylamine N-oxide (TMAO); TNF-alfa

Summary: salivary and serum levels of tmao and tnf-α can distinguish between individuals with periodontitis and periodontally healthy individuals.

trimethylamine n-oxide (tmao), a gut flora-derived metabolite from dietary choline, has emerged as an indicator of atherosclerosis. circulatory tmao has been implicated in cardiovascular risks by altering enterohepatic cholesterol and bile acid metabolism, increasing macrophage scavenger receptor expression, and activating nuclear factor kappa b (nf-κb) via pro-inflammatory genes such as interleukin-1 (il-1). the pro-inflammatory cytokine tumor necrosis factor-alpha (tnf-α), which plays a crucial role in immune responses and inflammation, has been demonstrated as a crucial participant also during the development of periodontal diseases. the aim of this study is to evaluate difference in salivary and serum levels of tmao and tnf-α between individuals with periodontitis and periodontally healthy individuals. the study includes two groups: systemically and periodontally healthy control subjects (n= 24), and patients with periodontitis (n=24). periodontal parameters were recorded. tmao levels in saliva and serum were determined by liquid chromatography-mass spectrometry (lc-ms/ms), and tnf-α levels were determined by elisa.

Eligibility criteria:
inclusion criteria: * being over 18 and under 65 years of age; * having at least 20 natural teeth excluding the third molars; and * being systemically healthy. exclusion criteria: * being smoker; * chronic use of any systemic medication * use of antibiotics and/or anti-inflammatory steroids, nonsteroidal anti-inflammatory drugs, immunosuppressants, beta-blockers, calcium channel blockers, anticoagulants, or hormonal contraceptives within 3 months preceding the study; * pregnancy or lactation; and * use of orthodontic appliances

Keywords: periodontal disease tmao tnf-α periodontitis
assessment of the performance of a new reduced noise mask vent

Conditions: Obstructive Sleep Apnoea (OSA)

Summary: as continuous positive airway pressure is the treatment of choice for osa, a mask is vital in ensuring the effectiveness of therapy delivery. the study will evaluate the performance and usability of the new mask vent. this is done by comparing the apnea-hypopnea index (ahi) of patients, who will apply 2 different washing procedures to the new mask, at the end of the study and their baseline data obtained at the beginning of the study.the study will also assess the breathing comfort as well as obtaining subjective data on the usability of the new mask vent system.


Eligibility criteria:
inclusion criteria: * subjects who are using resmed mask * subjects willing to provide written informed consent * subjects who have been treated for osa \> 6 months * subjects who can read and comprehend english * subjects ≥ 18 years old * subjects who are using a resmed s8 or s9 device exclusion criteria: * patients who are pregnant * patient on bi level treatment * patients being treated for osa \< 6 months * patients who have a pre-existing lung disease/condition that would predispose them to pneumothorax (for example: copd; lung cancer, fibrosis of the lungs; recent (\<2 years ago) case of pneumonia or lung infection; lung injury). * patients who are deemed unsuitable by the researcher due to the following reasons: * they do not comprehend english * they are unable to provide written informed consent * they are physically unable to comply with the protocol
a safety and efficacy study of mim-d3 ophthalmic solution for the treatment of dry eye

Conditions: Dry Eye Syndromes

Summary: the purpose of this study is to assess the safety and efficacy of mim-d3 ophthalmic solution compared with placebo ophthalmic solution in treating the signs and symptoms of dry eye.


Eligibility criteria:
inclusion criteria: * be at least 18 years of age * provided written informed consent * have a reported history of dry eye * have a history of use or desire to use eye drops for dry eye exclusion criteria: * be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation (e.g. follicular conjunctivitis) at visit 1, or have been diagnosed with ocular rosacea, or any viral or bacterial disease of the cornea or conjunctiva, within the last 12 months * have any planned ocular and/or lid surgeries over the study period * have corrected visual acuity greater than or equal to +0.7 as assessed by early treatment of diabetic retinopathy study (etdrs) scale in both eyes at visit 1 * have an uncontrolled systemic disease * be a woman who is pregnant, nursing or planning a pregnancy * be a woman of childbearing potential who is not using an acceptable means of birth control; acceptable methods of contraception include: hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom; iud; or surgical sterilization of partner. for non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the study, she must agree to use adequate birth control as defined above for the remainder of the study * have a known allergy and/or sensitivity to the test article or its components * have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study * be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 45 days of visit 1 * be unable or unwilling to follow instructions, including participation in all study assessments and visits
continuous glucose monitor for mayo clinic advanced care at home patients

Conditions: Diabetes Mellitus

Summary: the purpose of this study is to measure differences in diabetes control with the use of continuous glucose monitor (cgm) and diabetes education compared with standard of care for glucose monitoring (glucometer checks) and diabetes education in participants with diabetes mellitus receiving therapy with insulin and being admitted to mayo clinic advanced care at home program (ach).


Eligibility criteria:
inclusion criteria: * patients who are admitted to advanced care at home (ach) program and supposed to remain in ach for at least 72 hours. * patients with previous diagnosis of dm type 1 or type 2. * patients taking subcutaneous (sq) insulin either via multidose injections or sq insulin pump. * capable of giving signed informed consent exclusion criteria: * actively treated for diabetes ketoacidosis (dka) or hyperosmolar hyperglycemic state (hhs). * participants taking acetaminophen more than 4g per day or more than 1gm every 6 hours. * participants with altered mental status. * participants diagnosed with dementia. * patients with suicidal ideations or experiencing suicidal behavior. * patients with liver cirrhosis. * patients with end stage renal disease on dialysis bot hemodialysis or peritoneal dialysis. * participants with allergy to medical grade adhesive or medical tape. * participants taking hydroxyurea. * participants who are pregnant, wanting to become pregnant, or nursing during study period. * patients with a planned mri within the following 10 days after admission to ach. * participants currently using continuous glucose monitor (cgm) to dose insulin or check glucose level. * participants with diabetes mellitus (dm) treated with diet alone. * participants with dm treated with oral hypoglycemic medications. * participants with dm treated with one sq insulin injection daily. * participants enrolled in other studies addressing cgm use. * participants physically or emotionally incapable of handling a cell phone with a smart display. * participants with hearing impaired to a degree that they are not able to hear a smart phone alert or alarm. * patients lacking wifi or cellular coverage needed to connect the monitoring cell phone to internet network.

Keywords: advanced care at home program (home hospital)
effect of music therapy on anxiety of caregivers of alzheimer's disease patients

Conditions: Alzheimer Disease

Summary: this clinical trial evaluates the impact of music interventions on caregivers of patients with memory disorders, alzheimer's disease, dementia and related disorders. this study will follow caregivers of patients within the rehabilitation day care hospital "memory and frailty" (hôpital de jour de réadaptation mémoire et fragilités), sainte-marie paris hospital.

this clinical trial evaluates the impact of music on caregivers of patients with memory disorders, alzheimer's disease, dementia and related disorders. this study will follow caregivers of patients within the rehabilitation day hospital "memory and frailty " (hôpital de jour de réadaptation mémoire et fragilités), sainte-marie paris hospital. all participants will benefit from a first session of a relaxation-type musical technique in the day care hospital (hdj), they will then follow the sessions in their own homes. during the first visit, all participants will complete self-assessments, including a questionnaire on musical preferences and a self-assessment anxiety scale. the expected inclusion period is 30 days. carers will be equipped with tablets, headphones, eye masks and workbooks/questionnaires to use every day for one month in their homes. a relaxation-type receptive musical technique is used. the standardized 20-minute musical sequence is broken down into several phases that gradually lead the patient to a state of relaxation using the new u technique. the effect works by reducing the musical rhythm, orchestral formation, frequencies and volume (the "u" descending phase). after a maximum relaxation phase (lower part of the "u"), a re-activating phase (ascending branch of the "u") follows. all the musical sequences, built with the u-shape editing method, were specially produced by the music publishing company music care©. during the first session in hdj, the subjects will lie on a relaxation table with a raised headrest (extended or semi-seated listening position) in an enclosed space, calm, secure and comfortable, with minimum lighting, so that the participant feels comfortable. the music will be played on headphones. the main objective is to reduce anxiety among carers who accompany patients with memory disorders, alzheimer's disease and related dementia.

Eligibility criteria:
inclusion criteria: * anxiety self-assessment score (stai) greater than 46 at day 1 * patient relationship (child, spouse, brother/sister) exclusion criteria: * presence of a psychiatric disorder * intellectual disability * major hearing loss * professional musician

Keywords: music intervention alzheimer anxiety